Bd announces enrollment in post-market studies of the wavelinq™ arteriovenous endovascular fistula

Franklin lakes, n.j., april 29, 2021 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, connect-av.
BDX Ratings Summary
BDX Quant Ranking